Patents Assigned to United Therapeutics Corporation
  • Publication number: 20210177787
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 25, 2021
    Publication date: June 17, 2021
    Applicant: United Therapeutics Corporation
    Inventor: Michael WADE
  • Publication number: 20210179528
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Application
    Filed: November 30, 2020
    Publication date: June 17, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh BATRA, Vijay SHARMA, Sanmin YANG, Yi ZHANG
  • Publication number: 20210169939
    Abstract: Provided are methods for isolating potent extracellular vesicle populations from mesenchymal stem cells. In particular, the present disclosure identified a protein profile specific for MSC-derived EV populations. Moreover, disclosed herein is the use of the isolated extracellular vesicles in treating a variety of diseases and conditions, including chronic or acute lung diseases such as pulmonary hypertension, ARDS and diseases and conditions characterized by vasculopathy, reduced angiogenesis, apoptosis, mitochondrial dysfunction, acute inflammation, fibrosis, or chronic inflammation.
    Type: Application
    Filed: December 2, 2020
    Publication date: June 10, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Roger Ilagan, Sarah Hogan, John Cheadle, Carolina Papu
  • Publication number: 20210154238
    Abstract: Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.
    Type: Application
    Filed: February 1, 2021
    Publication date: May 27, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Sarah HOGAN, Roger Marquez ILAGAN, Maria Pia RODRIGUEZ, Carolina MEDRANO, John CHEADLE
  • Publication number: 20210139535
    Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
    Type: Application
    Filed: January 21, 2021
    Publication date: May 13, 2021
    Applicants: United Therapeutics Corporation, The United States of America as Represented by the Secretary, Department of Health & Human Services
    Inventors: David Meh, Timothy Atolagbe, G. Mark Farquharson, Samir Shaban, Mary Koleck, George Mitra
  • Patent number: 11001551
    Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: May 11, 2021
    Assignee: United Therapeutics Corporation
    Inventor: Peter Laing
  • Publication number: 20210121433
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Application
    Filed: January 4, 2021
    Publication date: April 29, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Ken PHARES, Hitesh BATRA, Liang GUO, Adam Marc SILVERSTEIN
  • Patent number: 10946047
    Abstract: Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: March 16, 2021
    Assignee: United Therapeutics Corporation
    Inventors: Sarah Hogan, Roger Marquez Ilagan, Maria Pia Rodriguez, Carolina Medrano, John Cheadle
  • Patent number: 10947177
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: March 16, 2021
    Assignee: United Therapeutics Corporation
    Inventor: Ken Phares
  • Publication number: 20210062157
    Abstract: Described herein are methods and compositions for use in expanding alveolar epithelial cells. The methods may include the use of three-dimensional substrates and improved techniques for expansion of the cells. The improved composition for culturing alveolar epithelial cells may include at least one or more of the following: a TGF-? pathway inhibitor; a Wnt pathway activator; a ROCK inhibitor; an epidermal growth factor (EGF); a keratinocyte growth factor (KGF); and a fetal bovine serum.
    Type: Application
    Filed: August 26, 2020
    Publication date: March 4, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Laila Roudsari, Daren Robinson, Benjamin Rusche, Sajini Nair, Ashley R. Dockham
  • Publication number: 20210054009
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Application
    Filed: August 24, 2020
    Publication date: February 25, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Kenneth Robert Phares, Hitesh Batra, Liang Guo
  • Publication number: 20210052641
    Abstract: A method for treating inflammatory diseases is provided. The method may include administering to a subject in need thereof a therapeutically effective amount of isolated extracellular vesicles or exosomes obtained from mesenchymal stem cells pre-conditioned with at least TNF-?. The isolated extracellular vesicles or exosomes may exhibit (a) enhanced expression of flotillin-1, (b) enhanced expression of CD73, or (c) enhanced expression of IDO. A method of isolating extracellular vesicles or exosomes capable of treating an inflammatory disease is also provided, wherein the method may include (a) culturing stem cells in a growth medium, (b) then culturing the stem cells in a starve medium supplemented with at least TNF-?, and (c) separating exosomes or extracellular vesicles from the culture. Cultures suitable for treatment are also provided.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 25, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Pamela Tiet, Roger Ilagan
  • Publication number: 20210030812
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Application
    Filed: October 16, 2020
    Publication date: February 4, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Patent number: 10906935
    Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: February 2, 2021
    Assignees: United Therapeutics Corporation, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: David Meh, Timothy Atolagbe, G. Mark Farquharson, Samir Shaban, Mary Koleck, George Mitra
  • Publication number: 20210008106
    Abstract: Methods and compositions relating to isolated mitochondria are disclosed. For example, cells, tissues, or organs can be treated with isolated mitochondria, such as porcine mitochondria, to improve mitochondrial function in the cell, tissue, or organ. The improvements to mitochondrial function include increased oxygen consumption and increased ATP synthesis. Such methods and compositions are useful for cell therapy; organ and tissue transplantation; organ and tissue engineering; and cold storage or shipment of harvested organs, tissues, and cells.
    Type: Application
    Filed: June 17, 2020
    Publication date: January 14, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Thomas Petersen, Sarah Hogan, Roger Ilagan, Caryn Cloer
  • Publication number: 20200368420
    Abstract: An apparatus for exchanging small molecules with a fluid includes a small-molecule conduit for providing a first fluid having a first type of small molecule, a target fluid conduit for providing a target fluid having a second type of small molecule therein, and a carrier fluid conduit for providing a carrier fluid that is configured (i) to receive at least some of the first type of small molecule from the first fluid and transfer at least some of the first type of small molecule to the target fluid and (ii) to receive at least some of the second type of small molecule from the target fluid and transfer at least some of the second type of small molecule to the first fluid. The apparatus further includes an exchange module having an exchange chamber in fluid communication with the small-molecule conduit, the target fluid conduit and the carrier fluid conduit.
    Type: Application
    Filed: May 22, 2020
    Publication date: November 26, 2020
    Applicant: United Therapeutics Corporation
    Inventor: Anna M. Galea
  • Publication number: 20200369592
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • Patent number: 10842823
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 24, 2020
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Publication number: 20200352157
    Abstract: An automated bioreactor system for decellularizing an organ includes a main chamber for containing the organ. The system further includes a reagent chamber containing a liquid phase reagent. A reagent conduit delivers the liquid phase reagent to the main chamber, and a perfusion conduit delivers the reagent from the reagent outlet in the main chamber into the organ. A perfusion pump drives the flow of the reagent. A perfusion pressure sensor detects a pressure of the flowing reagent. A control system controls the perfusion pump to drive the flow of the reagent based on a received input representative of a desired pressure and a received input of the detected pressure. The control system may automatically perform all of the steps of a decellularization protocol based on sensor input. An automated waste decontamination system may also be provided.
    Type: Application
    Filed: July 29, 2020
    Publication date: November 12, 2020
    Applicant: United Therapeutics Corporation
    Inventors: Ryan Bonvillain, John Cheadle, Thomas Petersen
  • Publication number: 20200345956
    Abstract: An adjustable aerosol delivery device includes an active liquid container, a carrier liquid container, a piezo disc mounted with a flexible gasket relative to the carrier liquid container, an oscillator configured to generate an ultrasonic wave that causes the piezo disc to oscillate and transmit the oscillations through the carrier liquid to the active liquid to cause at least a portion of the active liquid to become an aerosol, a bushing fixed relative to the carrier liquid container via a fixing portion that conforms to and mates with an entire perimeter of a fixing section of the bushing, and a fastener extending through the piezo disc housing and into the bushing. The fastener is configured to be loosened or tightened to manipulate a compression of the gasket to adjust a particle size of the aerosol. A pull force of the bushing is greater than a counter force of the gasket.
    Type: Application
    Filed: July 15, 2020
    Publication date: November 5, 2020
    Applicant: United Therapeutics Corporation
    Inventor: Doug Biette